LifeSensors, Inc. Launches their Ubiquitin Pathway Enzymes Assay Kits Licensed from Progenra, Inc.

MALVERN, Pa.–LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools and protein microarrays, announced today the launch of their CHOP2 Reporter assay kits for deubiquitylases (DUBs) and the imminent launch of their ubiquitin ligase assay kits. These proprietary technologies were developed by and licensed from Progenra, Inc. (www.progenra.com). The conjugation and deconjugation of ubiquitin and ubiquitin-like proteins (UBLs) are areas of intense interest within the academic and pharmaceutical communities due to their central roles in human heath and disease. It is likely that many pioneering drugs will emerge from research on ubiquitin and ubiquitin-like protein pathways. The assay platforms will aid in the identification and further characterization of the approximately 100 DUBs and 700 ligases in the human genome. Ongoing drug discovery and development programs by Progenra and others demonstrates the utility of these assay platforms to identify and characterize novel modulators of DUBs and ligases.

Among the key benefits of the CHOP Reporter Assay Kits include sensitive, rapid, and robust, fluorescent readouts of enzymatic activity within 30 mins with minimal interference from screening compounds. Currently, two CHOP reporter enzymes are available (CHOP1 and CHOP2) enabling multiplexing. The CHOP reporter platform is superior to traditional off-the-shelf assay technologies and will play a major role in drug discovery and diagnostics.

According to Jeffrey Boily, LifeSensors’ Chief Operating Officer, “The new CHOP2 assay kit further demonstrates LifeSensors’ leadership in SUMO and Ubiquitin tools and Technologies, enabling our customers to achieve breakthroughs in research and in therapeutic and diagnostic markets.”

Michael Mattern PhD, Vice President Research and COO of Progenra commented, “We have successfully used the CHOP reporters and the E3 ligase assay platforms to identify novel small molecule inhibitors of numerous DUBs and ligases and are happy to license our proprietary assay technologies to LifeSensors, Inc., a proven leader in the commercialization of ubiquitin pathway tools and reagents.”

About LifeSensors, Inc.

LifeSensors, Inc. is a biotechnology company that discovers, develops, manufactures, and markets protein expression technologies. Its customers are pharmaceutical and biotechnology companies worldwide as well as academic and government institutions. For more information on the new line of products, please refer to the web site at www.lifesensors.com.

About Progenra, Inc.

Progenra, Inc. is a world leader in ubiquitin pathway and drug discovery research. Its mission is to discover and develop pioneering medicines for unmet medical needs. The company is committed to wider application of its licensed technology for academia and industry.